Lisdexamfetamine
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Lisdexamfetamine (lisdexamfetamine dimesylate) — Vyvanse, Elvanse — is a synthetic stimulant of the amphetamine class. It is a prodrug of d-amphetamine, distinguished by its extended duration and reduced abuse potential. d-Amphetamine released from LDX reverses the dopamine and norepinephrine transporters, producing its effects by flooding synapses with catecholamines that drive attention, motivation, and arousal.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
dextroamphetamine, amphetamine, methamphetamine +1 moredextroamphetamine, amphetamine, methamphetamine, methylphenidate show less
Developed by New River Pharmaceuticals as an abuse-deterrent reformulation of d-amphetamine, LDX received FDA approval in 2007 as the first Schedule II stimulant prodrug in the United States.[2] Indications expanded to adult ADHD (2008) and binge eating disorder (2015) — LDX remains the only FDA-approved pharmacotherapy for BED as of 2026.[3] Generic formulations became available in 2023; it is a Schedule II controlled substance in all approved markets.
Subjective effects include enhanced sustained attention, increased motivation, psychomotor activation, appetite suppression, and mood elevation. The experience is defined by its gradual onset and broad plateau — a steady-state cognitive sharpening without the acute surge or crash of immediate-release stimulants. Insomnia, jaw tension, appetite loss extending into evening hours, and rebound effect fatigue are characteristic unsought effects.
LDX produces psychological dependence with chronic use, and cardiovascular stress is the primary toxicity concern — the drug is contraindicated in structural heart disease and uncontrolled hypertension.[4] The prodrug design blunts the rate of dopamine rise that drives compulsive redosing, substantially reducing but not eliminating abuse liability.[5] LDX is well-characterized across nearly two decades of clinical trials and post-marketing surveillance.[6]
History[edit]
Discovery
Lisdexamfetamine was created by New River Pharmaceuticals in Blacksburg, Virginia, with the explicit goal of building an amphetamine that resisted abuse. The compound — designated NRP104 — conjugated d-amphetamine to the amino acid L-lysine via an amide bond, rendering it pharmacologically inert until red blood cells cleaved the bond and liberated the active drug.[7] A pivotal abuse-liability study confirmed the design worked: intravenous LDX produced drug-liking scores indistinguishable from placebo, while equivalent IV d-amphetamine produced significant euphoria.[5]
Clinical Adoption
The FDA approved Vyvanse on 23 February 2007 for pediatric ADHD, making it the first Schedule II stimulant prodrug on the US market.[2] Shire Pharmaceuticals acquired New River for approximately $2.6 billion the same month. The label expanded to adult ADHD in 2008 and to moderate-to-severe binge eating disorder in January 2015 — the first and still only FDA-approved BED pharmacotherapy.[3][8]
Global Expansion and Generics
European approvals under the brand name Elvanse began in 2012–2015 across the United Kingdom, Germany, Spain, and Scandinavia.[9] Japan approved Vyvanse for pediatric ADHD in March 2019.[10] Following patent expiry, generic formulations received FDA approval in 2023.[2] As of 2026, a Phase 2 trial is investigating LDX as agonist replacement therapy for methamphetamine use disorder.[11]
The name "lisdexamfetamine" encodes the compound's structure: lis- derives from lysine, the amino acid conjugated to dexamfetamine (d-amphetamine). The brand name Vyvanse — suggesting "vivid" and "advance" — was chosen to evoke cognitive clarity. Among patients the drug is colloquially shortened to "Vyvanse" or "Elvanse" depending on market; no significant street-name culture exists, reflecting its primary circulation within prescription channels rather than illicit markets.
Chemistry[edit]
Structural Class
Lisdexamfetamine is a substituted amphetamine that functions as a prodrug — a pharmacologically inactive molecule designed to release an active drug inside the body. The parent compound is d-amphetamine, to which the amino acid L-lysine is attached via an amide bond at the amine group.[7] This lysine conjugation renders the molecule inert until enzymes in red blood cells cleave the bond, liberating d-amphetamine and free lysine.
The molecule retains the phenethylamine core of d-amphetamine (phenyl ring, two-carbon chain, α-methyl group) extended by lysine's six-carbon side chain terminating in a primary amine. The amide bond is the site of enzymatic hydrolysis.[7]
Molecular Properties
| Molecular formula | C₁₅H₂₅N₃O (free base) |
| Molecular weight | 263.38 g/mol (free base); 455.49 g/mol (dimesylate salt) |
The pharmaceutical form is the dimesylate salt (two methanesulfonic acid counterions), which provides improved crystalline stability and aqueous solubility relative to the free base.[12] The capsule contents may be dissolved in water for administration, reflecting the salt's aqueous solubility.[4]
Stereochemistry
Lisdexamfetamine contains two chirality centres, both in the (S)-configuration. The d-amphetamine moiety retains the (S)-configuration at the α-carbon — the pharmacologically active dextro-enantiomer — while the lysine moiety maintains the natural L-configuration.[12] Stereochemical integrity matters: d-amphetamine is substantially more potent at dopamine and norepinephrine transporters than its mirror image, l-amphetamine.[13]
Pharmacology[edit]
Mechanism of Action
Lisdexamfetamine is itself pharmacologically inert. After oral ingestion, enzymes in red blood cells cleave the lysine–amphetamine bond, releasing d-amphetamine (the active drug) and free L-lysine.[7][1]
d-Amphetamine acts through three converging mechanisms. First, it enters nerve terminals via the DAT (DAT) and NET (NET), then reverses these transporters to flood the synapse with dopamine and norepinephrine.[13][1] Second, it disrupts vesicular storage (VMAT2), dumping monoamines from storage vesicles into the cell interior where they become available for release.[10] Third, it competitively blocks reuptake at DAT and NET, slowing clearance of released catecholamines.[10]
The net result is a large, sustained increase in synaptic dopamine and norepinephrine — most prominently in the prefrontal cortex and striatum. d-Amphetamine also releases serotonin via SERT, though with much lower potency (DA >> NE >> 5-HT).[13] This serotonergic activity is too weak to produce MDMA-like empathogenic effects but contributes to interaction risks with other serotonergic drugs.
d-Amphetamine additionally activates TAAR1 (TAAR1), which modulates dopaminergic and serotonergic transmission and may contribute to regulatory effects on monoamine release.[14]
Pharmacokinetics
LDX is absorbed from the small intestine via the peptide transporter PEPT1 — a carrier-mediated process that imposes a natural rate limit on uptake regardless of dose.[7] Food delays peak levels by approximately one hour but does not reduce total absorption, permitting administration with or without meals.[15]
Conversion to d-amphetamine occurs in red blood cells via an unidentified high-capacity enzyme system — not in the liver.[7] This RBC-mediated hydrolysis produces a lower peak concentration and later time-to-peak compared to immediate-release d-amphetamine, creating the smooth, extended pharmacokinetic profile that defines LDX.[16][17]
The prodrug itself is cleared rapidly (half-life under one hour), while liberated d-amphetamine has a half-life of 9–15 hours.[15][18][16][4] Therapeutic effects persist for at least 13 hours in children and at least 14 hours in adults — longer than any other published long-acting amphetamine formulation.[16][19]
Elimination
d-Amphetamine is excreted by the kidneys. Urinary pH significantly alters elimination speed: alkaline urine (from antacids or sodium bicarbonate) slows excretion and prolongs effects, while acidic urine (from vitamin C or ammonium chloride) accelerates excretion and shortens duration.[4] This pH-dependent elimination is a class effect shared by all amphetamines.
Neuroscience[edit]
Where It Acts
d-amphetamine released from LDX produces its central effects by elevating dopamine in two key pathways: the mesolimbic projection (from ventral tegmental area to nucleus accumbens), which drives motivation and reward, and the mesocortical projection (to prefrontal cortex), which sharpens working memory and executive control.[1] Norepinephrine elevation in the prefrontal cortex strengthens signal-to-noise ratio in attention networks.
The therapeutic effects in ADHD arise primarily from the prefrontal pathway — restoring catecholamine levels to an optimal range where sustained attention and impulse control improve. In binge eating disorder, reduced thalamic activation during food cue processing suggests modulation of reward-salience circuits that drive compulsive eating.[20]
Why It Matters
Prefrontal catecholamine signalling follows an inverted-U curve: too little produces inattention (the ADHD baseline), optimal levels sharpen cognition, and too much causes rigidity and perseveration. LDX's gradual delivery may better approximate the optimal range across the day compared to immediate-release formulations with sharp peak-trough swings.[16]
The prodrug's blunted rate of dopamine rise also reduces incentive sensitisation — the progressive amplification of "wanting" that drives compulsive drug-seeking — relative to fast-onset stimulants.[21] Clinical efficacy in ADHD is generally maintained long-term without evidence of tolerance to cognitive benefits.[6]
The enzyme responsible for cleaving LDX in red blood cells has not been identified.[7] Whether genetic variation in this enzyme affects conversion speed and therapeutic response is unknown. The clinical significance of d-amphetamine's TAAR1 agonism relative to its transporter effects also remains undetermined.[14]
Subjective Effects[edit]
The lisdexamfetamine experience is one of quiet amplification — a steady-state cognitive sharpening that arrives without fanfare and sustains itself deep into the day. There is no acute rush or euphoric surge; instead, task engagement increases gradually, distractions lose their pull, and sustained effort feels effortless. At low-to-moderate doses the effect is largely cognitive; at higher doses, physical activation, jaw tension, and a driven restlessness emerge. Set and setting strongly modulate the character: in a structured work environment LDX facilitates productive flow, while in unstructured leisure it can produce purposeless hyperactivity or anxious rumination.
Compared to methylphenidate, LDX produces qualitatively similar cognitive enhancement but with a longer duration and a broader monoamine signature that adds subtle motivational warmth. Compared to MDMA or other serotonin-dominant releasers, the serotonergic component is negligible — LDX sits firmly in the cognitive-stimulant domain without empathogenic or prosocial character.[5]
Effect Grid
At common doses (30–50 mg oral), the full therapeutic profile is present: sustained enhancement of attention and concentration, meaningful reduction in impulsivity, improved executive function and working memory, and noticeable appetite suppression. Motivation and task-directed behaviour increase. Subjective experience is characterised by a steady, sustained cognitive clarity rather than an acute stimulant rush — the prodrug mechanism produces a gradual onset without a sharp peak.
Physically, heart rate increases of 4–6 BPM and systolic blood pressure rises of 1–2 mmHg are typical. Dry mouth, decreased appetite, and mild insomnia (if dosed late) are common. Headache and irritability occur in a minority of users.
Therapeutic duration spans 13–14 hours from ingestion. Sleep is typically impaired if the dose is taken after mid-morning.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sound sensitivity · Light sensitivity · Visual acuity enhancement · Visual processing acceleration · Brightness alteration · Tinnitus · Touch enhancement · Taste enhancement · After-images · Auditory hallucinations · Shadow people · External hallucinations · Internal hallucinations
Brightness alteration · Tinnitus · Touch enhancement · Taste enhancement · After-images · Auditory hallucinations · Shadow people · External hallucinations · Internal hallucinations
Pupil dilation · Dry mouth · Insomnia · Dehydration sensation · Restlessness · Heart rate perception changes · Bruxism · Respiratory stimulation · Excessive sweating · Muscle tension · Bodily lightness · Physical fatigue · Body high · Sexual arousal suppression · Spontaneous body sensations · Increased urination · Temperature dysregulation · Nausea · Sexual arousal enhancement · Headache · Motor control enhancement · Pain suppression · Constipation · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Trembling · Dizziness · Involuntary body movements · Motor control impairment · Vomiting · Nystagmus (eye wobbles)
Dehydration sensation · Restlessness · Heart rate perception changes · Bruxism · Respiratory stimulation · Excessive sweating · Muscle tension · Bodily lightness · Physical fatigue · Body high · Sexual arousal suppression · Spontaneous body sensations · Increased urination · Nausea · Sexual arousal enhancement · Headache · Motor control enhancement · Pain suppression · Constipation · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Trembling · Dizziness · Involuntary body movements · Motor control impairment · Vomiting · Nystagmus (eye wobbles)
Cognitive euphoria · Cognitive fatigue · Motivation enhancement · Thought organization · Memory enhancement · Analysis enhancement · Information processing enhancement · Pattern recognition enhancement · Novelty enhancement · Thought loops · Aesthetic enhancement · Cognitive flexibility · Multiple thought streams · Conceptual thinking · Creativity enhancement · Language enhancement · Motivation suppression · Thought deceleration · Introspection enhancement · Cognitive dysphoria · Humor enhancement · Cognitive impairment · Confusion · Thought disorganization · Delusions · Delirium
Thought organization · Memory enhancement · Analysis enhancement · Information processing enhancement · Pattern recognition enhancement · Novelty enhancement · Thought loops · Aesthetic enhancement · Cognitive flexibility · Multiple thought streams · Conceptual thinking · Creativity enhancement · Language enhancement · Motivation suppression · Thought deceleration · Introspection enhancement · Cognitive dysphoria · Humor enhancement · Cognitive impairment · Confusion · Thought disorganization · Delirium
Euphoria · Dysphoria · Emotional lability · Anhedonia
Compulsive behavior reduction · Sociability enhancement · Communication enhancement · Ego inflation · Social connection · Sociability suppression · Disinhibition · Social disconnection · Derealization · Depersonalization
Social connection · Sociability suppression · Disinhibition · Social disconnection · Derealization · Depersonalization
Timeline
First perceptible effects emerge as a subtle increase in alertness and mild mood brightening. The prodrug must be absorbed via PEPT1 and hydrolysed in red blood cells before d-amphetamine reaches effective concentrations, producing a slower onset than immediate-release amphetamine.
Focus sharpens progressively and appetite begins to diminish. Cognitive effects build steadily without the abrupt transition characteristic of IR stimulants. Mild cardiovascular activation (heart rate, blood pressure) becomes perceptible.
Maximum cognitive enhancement, sustained attention, and appetite suppression. d-Amphetamine Tmax occurs at 3. 0–4.
Therapeutic effects persist at a reduced but functional level. Focus and attention remain enhanced above baseline. Appetite suppression continues.
Effects gradually recede. Appetite returns, focus diminishes toward baseline, and fatigue may emerge as catecholamine levels normalise. Some users report mild irritability or mood dip during this phase.
Residual mild fatigue, possible mood flatness, and lingering appetite changes. Sleep architecture may remain disrupted even after subjective effects resolve, particularly at higher doses or with afternoon dosing.
⚠ Do not drive or operate heavy machinery during the comedown and evening hours following LDX use, as residual cognitive impairment and fatigue may persist beyond the subjective experience.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- dextroamphetamine · amphetamine · methamphetamine
Toxicity
Acute Toxicity
No human lethal dose has been established for lisdexamfetamine. Toxicity follows the amphetamine overdose spectrum[22]:
- Mild: agitation, rapid heart rate, elevated blood pressure, tremor
- Moderate: overheating, heavy sweating, vomiting, dilated pupils
- Severe: seizures, muscle breakdown, dangerous hyperthermia (>41°C), cardiovascular collapse
The prodrug design does not eliminate toxicity once d-amphetamine is liberated. However, the rate-limited conversion means oral overdose of LDX produces a slower rise in d-amphetamine blood levels than overdose of immediate-release amphetamine, potentially widening the window for medical intervention.
Cardiovascular Effects
At therapeutic doses, LDX reliably produces modest cardiovascular activation: heart rate increases of 4–6 BPM and systolic blood pressure rises of 1–2 mmHg.[3][23] These effects are dose-dependent and partially attenuate with continued use.
LDX is contraindicated in structural heart abnormalities, serious heart rhythm disorders, and moderate-to-severe high blood pressure.[4]
Growth Effects
Long-term stimulant use in children is associated with modest height and weight suppression. A 2-year European study confirmed this pattern in LDX-treated children and adolescents; ongoing growth monitoring is recommended for pediatric patients.[6]
Psychological Risks
Stimulants can unmask or worsen pre-existing psychiatric conditions. The following risks occur at therapeutic doses[4]:
- New-onset psychotic symptoms: hallucinations or paranoid thoughts, reported even in patients with no prior psychiatric history
- Mania or hypomania: risk in patients with undiagnosed bipolar disorder
- Tic worsening: pre-existing motor or vocal tics may intensify
- Anxiety and irritability: common across clinical populations
- Agitation: dose-dependent; may require dose reduction or discontinuation
Screening for personal and family psychiatric history is recommended before starting treatment.
Tolerance & Dependence
Tolerance to cardiovascular effects (heart rate, blood pressure) develops with continued use and is considered protective.[23] Tolerance to euphoria also develops, while therapeutic efficacy in ADHD is generally maintained during long-term treatment — the 2-year European study demonstrated sustained symptom improvement without evidence of cognitive tolerance.[6]
LDX is classified as DEA Schedule II with recognised abuse potential. The prodrug design substantially reduces the rapid euphoria onset that drives addictive patterns: intravenous LDX produces significantly lower drug-liking scores than intravenous d-amphetamine.[5] A comprehensive review confirmed reduced abuse potential for oral LDX compared to oral dexamphetamine.[21]
Stimulant withdrawal is characterised by low mood, fatigue, excessive sleep, appetite enhancement, and depression — reflecting depletion of monoamine stores after chronic elevated release.[24] These symptoms are not life-threatening but can be distressing. In the BED indication, discontinuation markedly increased binge eating relapse relative to continued treatment.[8]
Drug Interactions
MAOIs (Absolute Contraindication)
Co-administration with monoamine oxidase inhibitors — or use within 14 days of MAOI discontinuation — risks hypertensive crisis and serotonin syndrome from massive catecholamine accumulation.[4] A case report documented heart attack from combined MAOI, extended-release amphetamine, and psilocybin.[25]
Serotonergic Agents
The combination of LDX with other serotonin-active drugs raises the risk of serotonin syndrome — agitation, dangerous overheating, muscle rigidity, and altered consciousness. Tramadol is particularly risky due to additive serotonergic load and seizure threshold lowering.[26]
Sympathomimetic Agents
Co-administration with other stimulants (cocaine, high-dose caffeine) produces additive cardiovascular stress with risk of dangerous heart rhythm disturbances and hypertensive crisis.inferred
Urinary pH Modifiers
Alkalinising agents (sodium bicarbonate, antacids) reduce amphetamine excretion, prolonging and intensifying effects. Acidifying agents (vitamin C, ammonium chloride) accelerate excretion and shorten duration.[4]
Alcohol
No direct pharmacokinetic interaction occurs, but amphetamines mask alcohol's sedating effects, potentially leading to overconsumption and increased alcohol-related harm.citation needed
Contraindications
The following contraindications are established in prescribing information[4][27]:
Absolute:
- MAOI use within 14 days: hypertensive crisis and serotonin toxicity
- Hypersensitivity to amphetamine products or any excipient
- Structural heart abnormalities, serious arrhythmia: risk of sudden cardiac death under sympathomimetic stress
- Moderate-to-severe hypertension: amphetamine-induced blood pressure rise may trigger hypertensive emergency
- Hyperthyroidism: additive sympathomimetic activation
- Glaucoma: pupil dilation can trigger angle-closure crisis
- Agitated states: stimulation worsens agitation
Relative:
- History of drug abuse: increased misuse risk, though prodrug design provides partial protection
- Personal or family history of psychosis or bipolar disorder: risk of unmasking psychotic or manic episodes
- Tic disorders: risk of tic worsening
- Seizure disorders: amphetamines may lower seizure threshold at high doses
Harm Reduction[edit]
Forms & Identification
Lisdexamfetamine circulates almost exclusively as pharmaceutical capsules or chewable tablets in branded (Vyvanse, Elvanse) or generic packaging. The prodrug design means that diverted LDX is rarely encountered as loose powder on unregulated markets — its blunted euphoria profile makes it less attractive for non-medical diversion compared to immediate-release amphetamine.
For anyone receiving LDX outside a pharmacy chain of custody, verifying manufacturer markings and capsule imprints against published databases is the primary identification step. Reagent testing is of limited utility for pharmaceutical tablets but can confirm amphetamine class membership if contents are in doubt.
Guidelines
- Take the capsule in the morning with or without food; afternoon dosing risks severe insomnia
- Eat a substantial meal before dosing — appetite suppression makes eating difficult later
- Set hydration reminders; stimulants mask thirst signals and promote mild dehydration
- Plan a structured task list before the drug takes effect; directionless stimulation tends toward unproductive hyperfocus
- Do not crush, snort, or inject — the prodrug still requires enzymatic conversion in blood, making non-oral routes no more effective and potentially harmful
- Monitor resting heart rate; sustained readings above 100 BPM at rest warrant medical consultation
- Tolerance breaks ("drug holidays") under medical supervision may help maintain long-term efficacy
Set & Setting
LDX's 13–14+ hour duration means the drug shapes the entire waking day. Taking it in a structured environment with defined tasks tends to produce focused productivity; taking it without a plan can produce aimless hyperactivation or anxious rumination. Morning dosing is standard — afternoon administration risks insomnia lasting well past midnight.
Physical environment matters: adequate ventilation and temperature control help manage the mild thermogenic effect. Social context modulates the experience — isolated use can amplify obsessive focus on non-productive tasks.
Aftercare & integration. The LDX comedown is typically mild compared to immediate-release stimulants but can include rebound effect fatigue, irritability, and low mood in the evening hours. Planning for this transition helps: schedule low-demand activities after the drug's peak effect fades, and avoid making important emotional decisions during the tail.
Sleep recovery is the highest priority. Melatonin or a consistent wind-down routine can counteract residual wakefulness. Eat a full meal in the evening even if appetite remains suppressed — caloric deficit compounds next-day fatigue. If using LDX daily, track mood, appetite, and sleep quality over weeks to identify patterns that warrant dose adjustment.
Recovery & Support
Psychological dependence on prescribed stimulants often develops subtly — the line between therapeutic use and reliance on the drug for baseline functioning can blur over months or years. Signs include panic at the thought of missing a dose, dose escalation without medical guidance, and using the drug to avoid emotional states rather than to manage ADHD symptoms.
Tapering under medical supervision is the standard discontinuation approach. Support resources include prescriber-led dose reduction plans, cognitive-behavioural strategies for executive function without medication, and peer support communities for people navigating stimulant dependence. SMART Recovery and stimulant-specific online support groups provide non-judgmental frameworks for reassessing one's relationship with the medication.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency:
Most LDX side effects are uncomfortable but not dangerous. Seek immediate help if any of the following occur: chest pain or pressure, seizure activity, loss of consciousness, body temperature hot enough to feel through clothing, severe confusion or psychotic symptoms (auditory hallucinations, paranoid terror), or sustained heart rate above 150 BPM.
Immediate steps:
- 1. Call emergency services if any red-flag symptom is present
- 2. Move the person to a cool, quiet environment
- 3. Remove excess clothing; apply cool water to skin if overheating
- 4. Do not restrain unless there is immediate danger of self-harm
- 5. Do not induce vomiting
- 6. Keep the person talking and oriented if conscious
What to tell the dispatcher:
Name the substance (lisdexamfetamine/Vyvanse), approximate dose and time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug-related emergencies from prosecution.
No specific reversal agent exists for amphetamine overdose. Hospital treatment is supportive: cooling, sedation with benzodiazepines, and cardiovascular monitoring.
Legal Status[edit]
Lisdexamfetamine is a controlled substance in all jurisdictions where it is approved, classified at the most restrictive tier for medically available drugs. As a prodrug of d-amphetamine, LDX inherits the same scheduling despite its reduced abuse potential — regulatory authorities uniformly apply the control level of the active metabolite.[5][21]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | Marketed as Vyvanse; first approved 2007. Generic versions available since 2023. No refills permitted; new prescription required each fill[2] |
| United Kingdom | Class B, Schedule 2 (Misuse of Drugs Act 1971) | Marketed as Elvanse. Controlled drug prescription requirements apply[9] |
| European Union | Varies by member state | Approved as Elvanse in Germany, Spain, Denmark, Sweden, Norway, Finland, UK; as Tyvense in Ireland. Prescription-only in all approved markets[9] |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Marketed as Vyvanse. Controlled substance prescription requirements[9] |
| Australia | Schedule 8 (Controlled Drug) | Marketed as Vyvanse. Highest controlled drug tier for medical substances; strict prescribing and dispensing requirements[9] |
| Japan | Designated as raw material for stimulants | Marketed as Vyvanse. Approved March 2019 for pediatric ADHD. Subject to strict distribution controls under Japanese stimulant control law[10] |
Prodrug Scheduling Considerations
Despite demonstrated reduced abuse liability relative to immediate-release d-amphetamine, LDX has not received preferential scheduling in any jurisdiction. The regulatory principle is that the prodrug ultimately delivers the same controlled substance — the abuse-deterrent design mitigates but does not eliminate misuse potential. It is available exclusively by prescription, with no refills permitted under US Schedule II rules and comparable restrictions elsewhere.
references
- [1] ^abcdQuintero J, Gutiérrez-Casares JR, Álamo C (2022) Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review — Neurology and Therapy doi:10.1007/s40120-022-00392-2
- [2]
- [3] ^abcMcElroy SL, Hudson JI, Ferreira-Cornwell MC, et al. (2015) Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials — Neuropsychopharmacology doi:10.1038/npp.2015.275
- [4]
- [5]
- [6] ^abcdCoghill DR, Banaschewski T, Nagy P, et al. (2017) Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe — CNS drugs doi:10.1007/s40263-017-0443-y